Kata presented her work on CRISPR-Cas9 T cell pipeline optimisation at the American Society for Gene and Cell Therapy (ASGCT) conference in Washington D.C.

The poster below received a lot of interest from both the academic community and the industry, who appreciated that we do tool optimisation directly in primary cells and have high degree of automation available at our lab for cell work and downstream assays. 

Several interesting themes were covered at the conference, including most recent developments in prime editing, in vivo editing and ongoing gene therapy clinical trials.